Keywords: Psoriasis treatment, Abbott, Eisai, Humira, Amgen, Pfizer, Enbrel, Janssen, Stelara, Decision Resources

Abbott/Eisai's Humira has emerged as leading psoriasis agent

Article | 07 August 2012

Print This

For the treatment of psoriasis, Abbott/Eisai’s Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda’s Enbrel ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in